Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 19, Number 2—February 2013

Dispatch

Macrolide- and Rifampin-Resistant Rhodococcus equi on a Horse Breeding Farm, Kentucky, USA

Alexandra J. Burton, Steeve GiguèreComments to Author , Tracy L. Sturgill, Londa J. Berghaus, Nathan M. Slovis, Jeremy L. Whitman, Court Levering, Kyle R. Kuskie, and Noah D. Cohen
Author affiliations: Author affiliations: University of Georgia, Athens, Georgia, USA (A.J. Burton, S. Giguère, T.L. Sturgill, L.J. Berghaus); Hagyard Equine Medical Institute, Lexington, Kentucky, USA (N.M. Slovis); Equine Medical Associates, Lexington (J.L. Whitman, C. Levering); Texas A & M University, College Station, Texas, USA (K.R. Kuskie, N.D. Cohen)

Main Article

Table 1

Macrolide- and rifampin-resistant Rhodococcus equi on horse breeding farm, Kentucky, USA*

Year No. foals born No. (%) foals with lesions treated No. foals tested No. foals with positive R. equi culture No. (%) foals with macrolide- and rifampin-resistant R. equi
2001 95 30 (32) 30 30 0
2002 117 53 (45) 0 NA NA
2003 148 58 (32) 2 ? ?
2004 181 88 (49) 28 19 0
2005 168 70 (42) 30 ? ?
2006 170 42 (41) 5 2 0
2007 181 93 (51) 4 ? ?
2008 171 52 (30) 21 16 4 (25)†
2009 162 50 (31) 30 22 5 (23)†
2010 138 45 (33) 28 22 9 (41)†
2011 132 24 (18) 27 25 9 (36)†

*NA, not applicable; ?, data missing from farm records.
†Includes pretreatment and posttreatment isolates.

Main Article

1Current affiliation: Kalon Biotherapeutics LLC, College Station, Texas, USA.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO